Pfizer's Talzenna/Xtandi Combo Shows Over 50% Survival Improvement in Prostate Cancer Trial
PFE is trading near its 52-week low of $23.06 (13% above the low).
Summary
Pfizer announced strong Phase 3 trial results for its Talzenna and Xtandi combination therapy, demonstrating over 50% improvement in radiographic progression-free survival for metastatic prostate cancer patients. This significant clinical advancement for a major cancer indication could materially enhance Pfizer's oncology franchise and future revenue streams. The positive data adds to recent pipeline successes, including the Lyme disease vaccine and obesity asset acquisitions.
At the time of this announcement, PFE was trading at $26.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $149.2B. The 52-week trading range was $23.06 to $28.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.